Drug-tolerant persister cells in lymphoid malignancies: from mechanisms to therapeutic opportunities - Top-Institutions - MDSpire

Drug-tolerant persister cells in lymphoid malignancies: from mechanisms to therapeutic opportunities

  • By

  • Meng Li

  • Suping Tang

  • Peng Yang

  • Hao Zhou

  • July 15, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Hematology
    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Hematology
    • Oncology

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Hematology
    • Oncology

Original Source(s)

Drug-tolerant persister cells in lymphoid malignancies: from mechanisms to therapeutic opportunities

  • by Meng Li, Suping Tang, Peng Yang, Hao Zhou

  • July 15, 2026

Related Content

Prognostic significance of extracapsular extension in patients with non-small cell lung cancer following neoadjuvant chemoimmunotherapy: a retrospective cohort study

Mass Spec Roundup: Signals Recovered

This week’s stories span amino-metabolite imaging, site-specific HDX-MS, large-scale motif annotation, and proteomics missing-value recovery

  • July 15, 2026

  • 7 min
Helicobacter pylori infection in gastric cancer patients in French Guiana: a hospital-based study (2018–2023)